Insomnia (November)

Date of Issue: 11/01/2011 | Volume: 9 | Number: 11

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue

Article

Sleeping Pills: Which Ones for Which Patients?

Topics: Antidepressants | Antipsychotics | Benzodiazepines | Hypnotics | Mood Stabilizers

Insomnia is one of the most common comorbidities you’ll see in your depressed and anxious patients. But it is often misunderstood. While the common view is that insomnia is caused by a primary psychiatric or medical condition, it is more accurate to simply say that patients have insomnia and depression at the same time. Insomnia is almost never an isolated problem.

Read More
Article

The Carlat Guide to Medications Used for Insomnia

Topics: Antidepressants | Antipsychotics | Benzodiazepines | Hypnotics | Mood Stabilizers | Natural Medications

This handy table lists the medications most often used to treat insomnia.

Read More
Expert QA

Cognitive Behavioral Therapy for Insomnia (CBT-I)

In our study of CBT-I, we assigned participants with chronic and primary insomnia to either CBT-I, temazepam, a combination of the two, or placebo. We found that combination therapy was more effective than either treatment alone—in our study, the percentage reduction of time awake after sleep onset was highest for the combined condition (63.5%), followed by CBT (55%), temazepam (46.5%), and placebo (16.9%).

Read More
Research Update

Switching Antipsychotics Reduces Cardiovascular Risk Factors

Topics: Antipsychotics

If patients are stable on olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal) but are experiencing adverse metabolic effects, it might make sense to switch to a medication that has a lower risk of causing such effects. But would such a switch reduce obesity and cholesterol at the risk of a relapse?

Read More
Research Update

FDA Warning: High Doses of Citalopram May Be Dangerous for the Heart

Topics: Antidepressants

The editors at TCPR, as well as many of you, received a notice issued by the FDA on August 24, 2011 warning us that citalopram (Celexa) at doses higher than 40 mg may cause dangerous prolongation of the QT interval, which can increase the risk of cardiac arrhythmias (including the potentially fatal torsade de pointes).

Read More